Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Newborn screening (NBS) for cystic fibrosis (CF) is increasingly being implemented and is soon likely to be in use throughout the United States, because early detection permits access to specialized medical care and improves outcomes. The diagnosis of CF is not always straightforward, however. The sweat chloride test remains the gold standard for CF diagnosis but does not always give a clear answer. Genotype analysis also does not always provide clarity; more than 1500 mutations have been identified in the CF transmembrane conductance regulator (CFTR) gene, not all of which result in CF. Harmful mutations in the gene can present as a spectrum of pathology ranging from sinusitis in adulthood to severe lung, pancreatic, or liver disease in infancy. Thus, CF identified postnatally must remain a clinical diagnosis. To provide guidance for the diagnosis of both infants with positive NBS results and older patients presenting with an indistinct clinical picture, the Cystic Fibrosis Foundation convened a meeting of experts in the field of CF diagnosis. Their recommendations, presented herein, involve a combination of clinical presentation, laboratory testing, and genetics to confirm a diagnosis of CF.

[1]  J. Haddow,et al.  Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians , 2002, Genetics in Medicine.

[2]  M. de Martino,et al.  Sweat testing in newborns positive to neonatal screening for cystic fibrosis , 2004, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[3]  Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[4]  J. Barben,et al.  Conductivity determined by a new sweat analyzer compared with chloride concentrations for the diagnosis of cystic fibrosis. , 2005, The Journal of pediatrics.

[5]  J C Olsen,et al.  A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. , 1994, The New England journal of medicine.

[6]  Durie Pr Pathophysiology of the pancreas in cystic fibrosis. , 1992 .

[7]  R. Parad,et al.  Early Pulmonary Manifestation of Cystic Fibrosis in Children With the ΔF508/R117H-7T Genotype , 2006, Pediatrics.

[8]  C. Castellani,et al.  Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening , 2007, Archives of Disease in Childhood.

[9]  Victoria M. Pratt,et al.  Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel , 2004, Genetics in Medicine.

[10]  Legrys Va Assessing quality assurance for sweat chloride testing. , 1992 .

[11]  M. Corey,et al.  Prediction of mortality in patients with cystic fibrosis. , 1992, The New England journal of medicine.

[12]  J. Goldblatt,et al.  Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. , 2001, The European respiratory journal.

[13]  D Markiewicz,et al.  The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). , 1990, The New England journal of medicine.

[14]  J. Dankert-Roelse,et al.  Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. , 2005, The Journal of pediatrics.

[15]  M. Rosenfeld Overview of published evidence on outcomes with early diagnosis from large US observational studies. , 2005, The Journal of pediatrics.

[16]  J. Yankaskas,et al.  Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. , 2007, The Journal of pediatrics.

[17]  M. Rosenfeld,et al.  Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. , 2004, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[18]  A. Togias,et al.  Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. , 2000, JAMA.

[19]  A. Clark,et al.  Cystic Fibrosis Diagnosed After 2 Months of Age Leads to Worse Outcomes and Requires More Therapy , 2007, Pediatrics.

[20]  C. Robertson,et al.  Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989‐1998) , 2000, The Medical journal of Australia.

[21]  R. Parad,et al.  Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. , 2004, Pediatrics.

[22]  M. Kosorok,et al.  Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. , 1997, The New England journal of medicine.

[23]  M. Rosenfeld,et al.  Guidelines for Implementation of Cystic Fibrosis Newborn Screening Programs: Cystic Fibrosis Foundation Workshop Report , 2007, Pediatrics.

[24]  L. Sirota,et al.  Faecal elastase 1 levels in premature and full term infants , 2003, Archives of disease in childhood. Fetal and neonatal edition.

[25]  R. Parad,et al.  Sweat testing infants detected by cystic fibrosis newborn screening. , 2005, The Journal of pediatrics.

[26]  Michael R Knowles,et al.  Genetic modifiers of lung disease in cystic fibrosis. , 2005, The New England journal of medicine.

[27]  P. Lebecque,et al.  Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. , 2002, American journal of respiratory and critical care medicine.

[28]  P. Farrell The Meaning of “Early” Diagnosis in a New Era of Cystic Fibrosis Care , 2007, Pediatrics.

[29]  I. Doull,et al.  The evaluation of a novel conductometric device for the diagnosis of cystic fibrosis , 2006, Annals of clinical biochemistry.

[30]  J. Massie,et al.  Diagnosis of cystic fibrosis after newborn screening: The Australasian experience—twenty years and five million babies later: A consensus statement from the Australasian paediatric respiratory group , 2005, Pediatric pulmonology.

[31]  J. Zieleński,et al.  Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. , 2005, The Journal of pediatrics.

[32]  J. Massie,et al.  The limitations of sweat electrolyte reference intervals for the diagnosis of cystic fibrosis: a systematic review. , 2007, The Clinical biochemist. Reviews.

[33]  P. Durie Pathophysiology of the pancreas in cystic fibrosis. , 1992, The Netherlands journal of medicine.

[34]  M. Laughon,et al.  Sweat‐testing in preterm and full‐term infants less than 6 weeks of age , 2005, Pediatric pulmonology.

[35]  R. Heim,et al.  Improved detection of CFTR mutations in Southern California Hispanic CF patients , 2001, Human mutation.

[36]  M. Seia,et al.  Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations , 2002, European Journal of Pediatrics.

[37]  M. Kosorok,et al.  Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! , 2005, The Journal of pediatrics.

[38]  C. Férec,et al.  Immunoreactive Trypsin/DNA Newborn Screening for Cystic Fibrosis: Should the R117H Variant Be Included in CFTR Mutation Panels? , 2006, Pediatrics.

[39]  K. Hardy,et al.  Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients , 2004, Human mutation.

[40]  L. Tsui,et al.  A mutation in CFTR produces different phenotypes depending on chromosomal background , 1993, Nature Genetics.

[41]  M. Corey,et al.  The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis , 2005, Human Genetics.

[42]  R. Amin,et al.  Fecal elastase-1: utility in pancreatic function in cystic fibrosis. , 2006, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[43]  U. Stephan Neonatal screening for cystic fibrosis , 1980 .

[44]  R. Laessig,et al.  Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. , 2005, The Journal of pediatrics.

[45]  V. Legrys,et al.  Testing diagnostic tests: why size matters. , 2005, The Journal of pediatrics.

[46]  M. Corey,et al.  Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements. , 1998, The Journal of pediatrics.

[47]  P. Pignatti,et al.  Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. , 1995, Human molecular genetics.

[48]  J. Nick,et al.  Manifestations of cystic fibrosis diagnosed in adulthood , 2005, Current opinion in pulmonary medicine.

[49]  G. Cutting,et al.  Genotype-phenotype relationships in cystic fibrosis. , 2000, The Medical clinics of North America.

[50]  G. Cutting,et al.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. , 1998, The Journal of pediatrics.

[51]  P. Farrell,et al.  Sweat chloride concentrations in infants homozygous or heterozygous for F508 cystic fibrosis. , 1996, Pediatrics.

[52]  M. Corey,et al.  Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. , 2006, American journal of respiratory and critical care medicine.

[53]  R E COOKE,et al.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. , 1959, Pediatrics.

[54]  J. Emerson,et al.  Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials , 2004, Pediatric pulmonology.

[55]  P. Quinton,et al.  Chloride impermeability in cystic fibrosis , 1983, Nature.

[56]  G. B. Strickler Modern Problems in Pediatrics , 1959 .

[57]  T. Dörk,et al.  Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens , 1997, Human Genetics.

[58]  A. Feranchak Hepatobiliary complications of cystic fibrosis , 2004, Current gastroenterology reports.

[59]  S. Sidney,et al.  Risk of Recurrent Childhood Arterial Ischemic Stroke in a Population-Based Cohort: The Importance of Cerebrovascular Imaging , 2007, Pediatrics.

[60]  B. Wilcken,et al.  Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. , 1990, The New England journal of medicine.

[61]  M. Corey,et al.  Age-Related Alterations of Immunoreactive Pancreatic Cationic Trypsinogen in Sera from Cystic Fibrosis Patients with and without Pancreatic Insufficiency , 1986, Pediatric Research.

[62]  F. Accurso,et al.  Complications associated with symptomatic diagnosis in infants with cystic fibrosis. , 2005, The Journal of pediatrics.

[63]  R. Parad,et al.  Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. , 2005, The Journal of pediatrics.

[64]  M. Corey,et al.  Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. , 2006, The Journal of pediatrics.

[65]  D. Stableforth,et al.  Sweat Sodium and Chloride Concentrations—Essential Criteria for the Diagnosis of Cystic Fibrosis in Adults , 1990, Annals of clinical biochemistry.

[66]  C. Castellani,et al.  algorithmsfibrosis: terminology and diagnostic , 2008 .

[67]  R. Sokol Infertility in men with cystic fibrosis. , 2001, Current opinion in pulmonary medicine.

[68]  R. Parad,et al.  Newborn screening for cystic fibrosis. , 2003, Pediatric annals.

[69]  M. Fallin,et al.  Phenotypic and genetic characterization of patients with features of "nonclassic" forms of cystic fibrosis. , 2005, The Journal of pediatrics.

[70]  K De Boeck,et al.  Cystic fibrosis: terminology and diagnostic algorithms , 2005, Thorax.

[71]  M. Corey,et al.  Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. , 2004, Chest.

[72]  F. Accurso,et al.  Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. , 1992, The Journal of pediatrics.

[73]  Bridget Wilcken,et al.  Sweat testing following newborn screening for cystic fibrosis , 2000, Pediatric pulmonology.

[74]  A. Hamosh,et al.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. , 1996, American journal of human genetics.

[75]  H. Shwachman,et al.  Pilocarpine iontophoresis sweat testing results of seven years' experience. , 1967, Bibliotheca paediatrica.

[76]  M. Knowles,et al.  In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. , 1995, Human gene therapy.